Judah Frommer
Stock Analyst at Morgan Stanley
(4.16)
# 489
Out of 5,124 analysts
184
Total ratings
61.48%
Success rate
9.97%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVMN Evommune | Initiates: Overweight | $36 | $17.12 | +110.28% | 1 | Dec 1, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Overweight | $18 → $19 | $12.52 | +51.76% | 2 | Nov 14, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $34 → $37 | $36.31 | +1.90% | 1 | Nov 13, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $71 → $101 | $134.86 | -25.10% | 3 | Sep 12, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Equal-Weight | $25 → $26 | $25.12 | +3.50% | 2 | Jul 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Overweight | $46 → $43 | $27.16 | +58.32% | 2 | May 9, 2025 | |
| RGNX REGENXBIO | Maintains: Overweight | $22 → $24 | $14.41 | +66.55% | 2 | Mar 14, 2025 | |
| GLPG Galapagos NV | Downgrades: Underweight | $31 → $22 | $32.68 | -32.68% | 3 | Feb 14, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Underweight | $8 → $6 | $7.50 | -20.00% | 2 | Jan 13, 2025 | |
| ACLX Arcellx | Maintains: Overweight | $81 → $106 | $65.20 | +62.58% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $16.83 | +107.96% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $3 | $2.24 | +33.93% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $1.83 | +2,085.79% | 8 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $2.11 | +516.11% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $72.13 | -58.41% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $31.74 | -27.54% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $75.96 | -34.18% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $21.52 | +555.20% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $4.09 | +120.05% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $35.08 | -37.29% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $5.65 | +23.89% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $11.31 | -29.27% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $79.00 | -41.77% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $3.70 | +89.19% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $23.93 | +129.84% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $174.04 | -73.57% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $89.92 | -45.51% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $862.34 | -57.09% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $75.32 | -58.84% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $73.69 | +3.13% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $132.77 | +37.08% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $123.01 | -13.02% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $109.61 | -13.33% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $17.17 | +4.83% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $188.36 | -38.42% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $90.03 | -57.79% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $79.67 | -72.39% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $62.48 | -43.98% | 9 | Apr 29, 2020 |
Evommune
Dec 1, 2025
Initiates: Overweight
Price Target: $36
Current: $17.12
Upside: +110.28%
Trevi Therapeutics
Nov 14, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $12.52
Upside: +51.76%
Zenas BioPharma
Nov 13, 2025
Maintains: Overweight
Price Target: $34 → $37
Current: $36.31
Upside: +1.90%
ABIVAX Société Anonyme
Sep 12, 2025
Maintains: Overweight
Price Target: $71 → $101
Current: $134.86
Upside: -25.10%
Apellis Pharmaceuticals
Jul 2, 2025
Maintains: Equal-Weight
Price Target: $25 → $26
Current: $25.12
Upside: +3.50%
Celldex Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $46 → $43
Current: $27.16
Upside: +58.32%
REGENXBIO
Mar 14, 2025
Maintains: Overweight
Price Target: $22 → $24
Current: $14.41
Upside: +66.55%
Galapagos NV
Feb 14, 2025
Downgrades: Underweight
Price Target: $31 → $22
Current: $32.68
Upside: -32.68%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $7.50
Upside: -20.00%
Arcellx
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $65.20
Upside: +62.58%
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $16.83
Upside: +107.96%
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $2.24
Upside: +33.93%
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $1.83
Upside: +2,085.79%
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $2.11
Upside: +516.11%
Aug 9, 2023
Reiterates: Outperform
Price Target: $30
Current: $72.13
Upside: -58.41%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $31.74
Upside: -27.54%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $75.96
Upside: -34.18%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $21.52
Upside: +555.20%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $4.09
Upside: +120.05%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $35.08
Upside: -37.29%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $5.65
Upside: +23.89%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $11.31
Upside: -29.27%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $79.00
Upside: -41.77%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $3.70
Upside: +89.19%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $23.93
Upside: +129.84%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $174.04
Upside: -73.57%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $89.92
Upside: -45.51%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $862.34
Upside: -57.09%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $75.32
Upside: -58.84%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $73.69
Upside: +3.13%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $132.77
Upside: +37.08%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $123.01
Upside: -13.02%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $109.61
Upside: -13.33%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $17.17
Upside: +4.83%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $188.36
Upside: -38.42%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $90.03
Upside: -57.79%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $79.67
Upside: -72.39%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $62.48
Upside: -43.98%